Search

Displaying results 3671 - 3680 of 10000 in total
  1. Drug

    Xanomeline

    go.drugbank.com/drugs/DB15357
    ApprovedInvestigational

    [A264514] Xanomeline is a muscarinic agonist that was approved for the treatment of schizophrenia by the FDA in September 2024, becoming the first approved treatment for schizophrenia to target muscarinic … Schizophrenia is a complex disease involving a number of different neurotransmitters, including serotonin, dopamine, and acetylcholine.

  2. Drug

    Phenacetin

    go.drugbank.com/drugs/DB03783
    ApprovedWithdrawn

    Phenacetin was withdrawn from the Canadian market in June 1973 due to concerns regarding nephropathy (damage to or disease of the kidney).

  3. Drug

    Sertindole

    go.drugbank.com/drugs/DB06144
    ApprovedWithdrawn

    It is a phenylindole derivative used in the treatment of schizophrenia. … Sertindole, a neuroleptic, is one of the newer antipsychotic medications available. Serdolect is developed by the Danish pharmaceutical company H. Lundbeck.

  4. Drug

    Secukinumab

    go.drugbank.com/drugs/DB09029
    ApprovedInvestigational

    [L39600] By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. … Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque

    Products: SCAPHO (POWDER FOR SOLUTION FOR INJECTION), Fraizeron 150mg Powder for Solution for Injection
  5. Drug

    Butobarbital

    go.drugbank.com/drugs/DB01353
    ApprovedIllicit

    Butobarbital is a sedative and a hypnotic drug.

  6. Drug

    Vibostolimab

    go.drugbank.com/drugs/DB16420
    Investigational

    Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)). … Vibostolimab is under investigation in clinical trial NCT04303169 (Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With

  7. Drug

    Eniluracil

    go.drugbank.com/drugs/DB03516
    Investigational

    second line therapy for a variety of cancers including colorectal, breast, gastric, head and neck, ovarian and basal cell cancer of the skin. … Eniluracil could improve 5-FU by increasing its effectiveness, reducing its side effects and/or making it orally available.

  8. Drug

    Enmetazobactam

    go.drugbank.com/drugs/DB18716
    ApprovedInvestigational

    Enmetazobactam is a penicillanic acid sulfone extended-spectrum beta (β)-lactamase (ESBL) inhibitor. … [A263276] The combination product of enmetazobactam and [cefepime] was first approved by the FDA on February 23, 2024, for the treatment of complicated urinary tract infections.

  9. Drug

    GR270773

    go.drugbank.com/drugs/DB06427
    Investigational

    NCT00089986 (completed with results, treatment of suspected or confirmed gram-negative severe sepsis in adults, comparing GR270773 with a placebo). … GR270773, was investigated in two clinical trials for its potential to treat sepsis: NCT00158769 (completed, comparing the effects of infusion between healthy adults and those with damaged livers) and

  10. Drug

    Sulfameter

    go.drugbank.com/drugs/DB06821
    Approved

    Long acting sulfonamide used in leprosy, urinary, and respiratory tract infections.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use